COMPANY
TECHNOLOGY
MEDIA
CONTACT
PATIENTS
CLINICIANS
Select Page
Ultra-Focal
Patient Focused
Leveraging Nanoshells in the First True Focal Therapy
Nanospectra Biosciences is a medical device company pioneering a patient-centric use of namomedicine for selective thermal ablation.
Company
Delivering on the

‘Nanomedicine Promise’
Nanospectra’s proprietary ultra-focal technology platform has demonstrated its safety and efficacy in initial clinical trials and is viable for multiple applications including solid tumors, tissue and drug delivery. The company is implementing a multi-prong growth strategy including clinical advancement, exclusive partnering agreements and ongoing research and development.
Learn More
Technology
Introducing the First Ultra-Focal Nanoshell Technology
Nanospectra’s proprietary AuroLase® Therapy utilizes ‘optical tunability’ for a new class of nanoparticles, called AuroShells®. These nanoshells convert light into heat and thermally destroy solid tumors without damaging adjacent healthy tissue.
Learn More
AUROLASE FOR PROSTATE CANCER
AuroLase for the Ablation of Prostate Cancer Tissue
AuroLase is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies.
Tumor Ablation using 
AuroLase Therapy
Click here for clinical trial information
Press Releases
Nanospectra Biosciences to Present at Texas Life Science Forum
November 5, 2018
Nanospectra Biosciences Technology Advances Partner  Products to US Commercialization
October 30, 2018
Nanospectra Biosciences’ Safety Data Presented  at 2018 AUA Conference
May 15, 2018
1
2
Company
Management
Advisors
Partners
Board
Investors
Technology
Overview
Scientific Publications
Animation
Media
News
Press Releases
Blog
Patients
Clinicians